At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 enrolled
Drug / intervention
Fexofenadine +1 moredrug
Likely dose
Fexofenadine 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study to Compare The Safety and Possible Efficacy of Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis
In Brief
A Phase 4 clinical trial evaluating Fexofenadine and Gabapentin for Uremic Pruritus and 5 related conditions. Completed, enrolled 60 participants across 1 site.
Detailed Summary
Several studies investigated the effectiveness of Gabapentin in Uremic Pruritus (UP). No previous studies investigated the use of fexofenadine in UP. The aim of this trial is to assess the safety and possible efficacy of fexofenadine in patients with UP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUremic Pruritus, Chronic Kidney Disease-associated Pruritus, Hemodialysis, End-stage Renal Disease, Renal Replacement Therapy, ESRD
CountriesEgypt
Collaborators--
Timeline
Phase 4CompletedFinished
20252026
First PostedJun 2024
Enrollment StartJul 2024
Primary CompletionOct 2024
Study CompletionDec 2024
TodayJul 2026
First PostedJun 20, 2024
Enrollment StartJul 1, 2024
Primary CompletionOct 1, 2024
Study CompletionDec 20, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.0 years ago
Interventions
Fexofenadinedrug
Fexofenadine 60 mg orally once daily for 3 months
Gabapentindrug
100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.